BIO - Rasio utang marang kapitalisasi buku Bio-Rad Corp

Bio-Rad Laboratories (BIO) develops instruments and tests for Life Science, generating revenue through the supply of high-margin consumables to hospitals and research institutes. Stable demand from clinics and the academic sector maintains the metric at 0.19. The share price illustrated below reflects the market dynamics of a business that provides scientists with the tools for the deep study of proteomics and genetics, facilitating medical breakthroughs.

This indicator reflects the ratio of total liabilities to equity, demonstrating the dependence of financial stability on the efficiency of operating flows. By analyzing the balance sheet debt-to-capitalization ratio, an investor assesses the credit risks of Bio-Rad Laboratories (BIO): the high margins of the reagent sales model allow the company to optimize leverage, as confirmed by the debt load dynamics on this chart.